Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo; Drug
Lead sponsor: Apotex Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Allergy
Interventions: Grazax; Drug
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine 1.25 mg, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Seasonal Allergic Rhinitis
Interventions: AIC (Amb a 1 Immunostimulatory Conjugate); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions: Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Conditions: Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions: Fluticasone propionate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Healthy
Interventions: Probiotic mixture, Placebo; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions: Bilastine, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more

Conditions: Seasonal Allergic Rhinitis
Interventions: QNASL, Placebo nasal spray; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Rhinitis
Interventions: Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Neptune City, New Jersey • Newark, New Jersey

Conditions: Allergic Rhinitis
Interventions: Placebo, VAK694, Fluticasone; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 41
States / cities: Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Hay Fever, Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal spray; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Beclomethasone dipropionate, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Oxford, Alabama • Encinitas, California • Huntington Beach, California + 31 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Allergy
Interventions: Standardized Allergenic Extract, Cat Hair, Placebo; Biological
Lead sponsor: Antigen Laboratories, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: San Diego, California • Marietta, Georgia • St Louis, Missouri

Conditions: Seasonal Allergic Rhinitis
Interventions: 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 29
States / cities: Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more

Conditions: Allergy Pollen
Interventions: Spiriplex Allergenex Microassay; Diagnostic Test
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rhinitis, Allergic, Seasonal, Hay Fever
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 6
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Search by objective public record fields.

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

A Trial of Grazax in Subjects With Hayfever

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

DNA Vaccine for Ragweed Allergic Adults

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Allergic Rhinitis Changes the Sinus Microbiome

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Phase 2 Study in Adults Sensitized to Cat

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

Microassay and Allergy Skin Prick Test Correlation Study

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)